Lumida
/MLYS
⌘K
Mineralys Therapeutics Inc

Mineralys Therapeutics Inc

MLYS
$27.09USD↑+0.04%+0.01 today

MARKET CAP

2.4B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$26 – $28

52W RANGE

$13
$48

AI Summary

Stalk
StalkMedium

MLYS remains in a Stage 2 advancing corrective reset with persistent higher highs and lows and rising intermediate EMAs, supporting a Bullish medium-term bias. However, price is extended far above the 9/21/50 EMA envelope and is marked by overbought RSI and extreme Options Score, making immediate entry unfavorable. We will Stalk, seeking pullbacks into the rising 9/21 EMA support zone for potential buy opportunities via pullback interaction.

  • ↑9.1 mmHg mean systolic reduction in LAUNCH-HTN/ADVANCE-HTN trials.
  • ↑$646 M cash on hand funds development and launch through 2028.
  • ↓Q1 2026 net loss of $39.3 M and rising G&A costs ($21 M) pressure margins.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Mineralis Therapeutics, Inc. (NASDAQ: MLYS) is a biotechnology company focused on developing innovative therapies for hypertension and related comorbid conditions. Their lead candidate, lorundrastat, is designed to address uncontrolled and resistant hypertension, a significant and unmet medical need impacting over 20 million patients in the U.S. The company aims to leverage lorundrastat's profile to establish itself as a leading player in the hypertension market, particularly as they prepare for the impending regulatory milestones and potential commercialization.

Bull says

  • ↑9.1 mmHg mean systolic reduction in LAUNCH-HTN/ADVANCE-HTN trials.
  • ↑$646 M cash on hand funds development and launch through 2028.
  • ↑95% of surveyed cardiologists intend to prescribe lorundrastat.
  • ↑1.93 13F institutional ownership highlights strong investor confidence.
  • ↑Expanding into CKD and OSA indications to broaden market reach.
  • ↑1.17% dividend yield and robust liquidity support shareholders.

Bear says

  • ↓Q1 2026 net loss of $39.3 M and rising G&A costs ($21 M) pressure margins.
  • ↓Negative profitability and significant leverage raise financial instability risks.
  • ↓AstraZeneca’s upcoming hypertension launch could erode market share.
  • ↓Analyst earnings revisions trending downward cloud future outlook.
  • ↓Hyperkalemia signals in CKD trials may hurt prescriber confidence.
  • ↓High payer-access barriers and survey intent may not convert to sales.

Investment themes with MLYS

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-07-2026bullish

Transcript signals

Bull points

  • We believe that our current cash, cash equivalents, and investments will be sufficient to fund our planned clinical trials and regulatory activities, as well as support corporate operations into 2028.
  • Total other income net was $6 million for the quarter ended March 31, 2026, compared to $2.2 million for the quarter ended March 31, 2025. The increase reflects higher interest earned on investments in our money market funds and U.S. Treasuries due to higher average cash balances invested during the quarter.
  • NDA acceptance in the first quarter has been the culmination of a massive effort by our team and our mission to provide more healthy days to patients with cardiovascular disease.

Bear points

  • Net loss was $39.3 million for the quarter ended March 31st, 2026, compared to $42.2 million for the quarter ended March 31st, 2025. The decrease was primarily attributable to the factors impacting our expenses that I just described.
  • Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company.
Read full transcript analysis ›